核因子-κB通路在甲状腺癌发生机制和治疗中的作用

The role of nuclear factor-κB pathway on carcinogenesis and therapy of thyroid cancer

甲状腺癌的发病率逐年增高,^131I治疗DTC虽是一种有效的治疗手段,但甲状腺癌的核素治疗失效也并不罕见.核因子-κB（NF-κB）在甲状腺癌细胞中的高表达与甲状腺癌的发生、进展、拮抗凋亡和产生耐药等均密切相关.NF-κB抑制剂对于甲状腺癌有明确的治疗效果,^131I联合NF-κB抑制剂治疗可以增加对甲状腺癌的疗效.

The incidence rate of thyroid cancer is increasing very rapidly during the past years.^131I treatment for DTC is an effective method.However,DTC refractory to ^131I treatment or therapeutic failure is not uncommon.High level expression of nuclear factor-kappa B （NF-λB） in thyroid cancer is closely related with carcinogenesis,progression,anti-apoptosis and therapeutic resistance.NF-κB inhibitor was effective for the treatment of thyroid cancer.Combined NF-κB inhibitor with^131I may improve the therapeutic efficacy.